Matches in SemOpenAlex for { <https://semopenalex.org/work/W2069454919> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W2069454919 endingPage "512" @default.
- W2069454919 startingPage "507" @default.
- W2069454919 abstract "Tocilizumab, a biological agent developed in Japan, is a human anti-interleukin-6 (anti-IL-6) receptor antibody. Rheumatoid arthritis improves with its use. A remission rate of 59% is attainable, as measured by disease activity score 28 (DAS28) in the SAMURAI study. However, in tocilizumab treatment, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) levels drop to negative values; therefore we sought to utilize a different index for measuring its efficacy. In order to evaluate the effects of tocilizumab we carried out this study using clinical disease activity index (CDAI), as it is not reliant on blood data and would also allow us to determine which markers are present in remission. Twenty-two patients under treatment with tocilizumab participated in this study. Effects of treatment as well as the remission rate were measured by CDAI and DAS28 3 months after initiation of treatment. IL-6 and matrix metalloproteinase-3 (MMP-3) levels were measured at the same time. We studied the clinical efficacy of tocilizumab using DAS28 after treatment; remission as measured by DAS28 was 57.1% at 1 year. However, the remission rate as measured by CDAI was only 19.1% at 1 year. CDAI was not only correlated with DAS28, but also other clinical variables, MMP-3, and IL-6. We conclude that CDAI is effective in measuring clinical response to tocilizumab treatment, and that MMP-3 level is as useful as IL-6 level as an indicator." @default.
- W2069454919 created "2016-06-24" @default.
- W2069454919 creator A5006840017 @default.
- W2069454919 creator A5009588650 @default.
- W2069454919 creator A5022049181 @default.
- W2069454919 creator A5043209626 @default.
- W2069454919 creator A5064424037 @default.
- W2069454919 creator A5082811992 @default.
- W2069454919 date "2009-07-17" @default.
- W2069454919 modified "2023-10-01" @default.
- W2069454919 title "Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level" @default.
- W2069454919 cites W1588610010 @default.
- W2069454919 cites W2012942026 @default.
- W2069454919 cites W2022079609 @default.
- W2069454919 cites W2022713850 @default.
- W2069454919 cites W2023761225 @default.
- W2069454919 cites W2084386397 @default.
- W2069454919 cites W2100039847 @default.
- W2069454919 cites W2108428852 @default.
- W2069454919 cites W2118742196 @default.
- W2069454919 cites W2139339400 @default.
- W2069454919 cites W2150952126 @default.
- W2069454919 cites W2164804018 @default.
- W2069454919 cites W4255569771 @default.
- W2069454919 doi "https://doi.org/10.1007/s10165-009-0203-z" @default.
- W2069454919 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19609487" @default.
- W2069454919 hasPublicationYear "2009" @default.
- W2069454919 type Work @default.
- W2069454919 sameAs 2069454919 @default.
- W2069454919 citedByCount "21" @default.
- W2069454919 countsByYear W20694549192012 @default.
- W2069454919 countsByYear W20694549192013 @default.
- W2069454919 countsByYear W20694549192014 @default.
- W2069454919 countsByYear W20694549192015 @default.
- W2069454919 countsByYear W20694549192016 @default.
- W2069454919 countsByYear W20694549192020 @default.
- W2069454919 countsByYear W20694549192022 @default.
- W2069454919 countsByYear W20694549192023 @default.
- W2069454919 crossrefType "journal-article" @default.
- W2069454919 hasAuthorship W2069454919A5006840017 @default.
- W2069454919 hasAuthorship W2069454919A5009588650 @default.
- W2069454919 hasAuthorship W2069454919A5022049181 @default.
- W2069454919 hasAuthorship W2069454919A5043209626 @default.
- W2069454919 hasAuthorship W2069454919A5064424037 @default.
- W2069454919 hasAuthorship W2069454919A5082811992 @default.
- W2069454919 hasConcept C11988809 @default.
- W2069454919 hasConcept C126322002 @default.
- W2069454919 hasConcept C198451711 @default.
- W2069454919 hasConcept C2777178219 @default.
- W2069454919 hasConcept C2777575956 @default.
- W2069454919 hasConcept C2778143017 @default.
- W2069454919 hasConcept C2778690821 @default.
- W2069454919 hasConcept C71924100 @default.
- W2069454919 hasConcept C90924648 @default.
- W2069454919 hasConceptScore W2069454919C11988809 @default.
- W2069454919 hasConceptScore W2069454919C126322002 @default.
- W2069454919 hasConceptScore W2069454919C198451711 @default.
- W2069454919 hasConceptScore W2069454919C2777178219 @default.
- W2069454919 hasConceptScore W2069454919C2777575956 @default.
- W2069454919 hasConceptScore W2069454919C2778143017 @default.
- W2069454919 hasConceptScore W2069454919C2778690821 @default.
- W2069454919 hasConceptScore W2069454919C71924100 @default.
- W2069454919 hasConceptScore W2069454919C90924648 @default.
- W2069454919 hasIssue "5" @default.
- W2069454919 hasLocation W20694549191 @default.
- W2069454919 hasLocation W20694549192 @default.
- W2069454919 hasOpenAccess W2069454919 @default.
- W2069454919 hasPrimaryLocation W20694549191 @default.
- W2069454919 hasRelatedWork W1987294331 @default.
- W2069454919 hasRelatedWork W2046399730 @default.
- W2069454919 hasRelatedWork W2069454919 @default.
- W2069454919 hasRelatedWork W2079529802 @default.
- W2069454919 hasRelatedWork W2141624058 @default.
- W2069454919 hasRelatedWork W2558297493 @default.
- W2069454919 hasRelatedWork W2636378421 @default.
- W2069454919 hasRelatedWork W2736593664 @default.
- W2069454919 hasRelatedWork W3007454014 @default.
- W2069454919 hasRelatedWork W3087945819 @default.
- W2069454919 hasVolume "19" @default.
- W2069454919 isParatext "false" @default.
- W2069454919 isRetracted "false" @default.
- W2069454919 magId "2069454919" @default.
- W2069454919 workType "article" @default.